KEYMED BIO-B (02162): It is recommended to issue shares in Renminbi and list on the Sci-Tech Innovation Board of the Shanghai Stock Exchange.

KEYMED BIO-B (02162) announced that on August 19, 2026, the Board of Directors of the company decided to propose the issuance of common stock to be listed and traded in RMB on the Shanghai Stock Exchange's Sci-Tech Innovation Board (the "Sci-Tech Innovation Board") (the proposed issuance of RMB shares). The proposed issuance of RMB shares is subject to and contingent upon (among other things) market conditions, further approval by the Board of Directors, approval by the company's shareholders at the shareholders' meeting, and obtaining necessary regulatory approvals. As of the date of this announcement, aside from the preliminary plan for the proposed issuance of RMB shares and information disclosed separately in this announcement, the Board of Directors does not have any other plans concerning the proposed issuance of RMB shares, nor has it submitted any applications regarding the proposed issuance of RMB shares to the relevant regulatory authorities.